Acute Management of Bradycardia in the Emergency Setting
Clinical evaluation
- –
- Presence, duration and gravity of symptoms (for how long has the patient been symptomatic? Was there syncope? If yes, did it result in trauma?)
- –
- Vital signs
- –
- Systemic repercussions of bradycardia and a lowoutput state (renal function, lactate, etc.)
- –
- Type of bradycardia (sinus, AVB II Wenckebach vs Mobitz 2, AVB III)
- –
- Presence or absence of a documented escape rhythm
- –
- Effect of pharmacological treatment (isoprenaline, atropine)
- –
- Anticipated duration of the bradycardia
Pharmacological therapy
Transcutaneous pacing
Transoesophaeal pacing
Transvenous pacing
Conclusions
Disclosure statement
References
- Soar, J.; Nolan, J.P.; Bottiger, B.W.; Perkins, G.D.; Lott, C.; Carli, P.; et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation 2015, 95, 100–147. [Google Scholar] [CrossRef] [PubMed]
- Morrison, L.J.; Long, J.; Vermeulen, M.; Schwartz, B.; Sawadsky, B.; Frank, J.; et al. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing versus conventional treatment: ‘PrePACE’. Resuscitation 2008, 76, 341–349. [Google Scholar] [CrossRef] [PubMed]
- Polyzos, K.A.; Konstantelias, A.A.; Falagas, M.E. Risk factors for cardiac implantable electronic device infection: A systematic review and meta analysis. Europace 2015, 17, 767–777. [Google Scholar] [CrossRef] [PubMed]
- Brignole, M.; Auricchio, A.; Baron Esquivias, G.; Bordachar, P.; Boriani, G.; Breithardt, O.A.; et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: The task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013, 15, 1070–1118. [Google Scholar]
- Priori, S.G.; Blomstrom Lundqvist, C.; Mazzanti, A.; Blom, N.; Borggrefe, M.; Camm, J.; et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015, 36, 2793–2867. [Google Scholar] [PubMed]
- Kawata, H.; Pretorius, V.; Phan, H.; Mulpuru, S.; Gadiyaram, V.; Patel, J.; et al. Utility and safety of temporary pacing using active fixation leads and externalized re usable permanent pacemakers after lead extraction. Europace 2013, 15, 1287–1291. [Google Scholar] [CrossRef] [PubMed]
Nodal block | Infranodal block | ||
Diagnostic / strongly suggestive | AVB II Wenckebach (may exceptionally be infranodal!) | AVB II Mobitz 2 | |
Long PR when conducting | Normal PR when conducting | ||
PP prolongation before AVB | No PP prolongation | ||
During sleep only | Occurs at exercise (e.g. isometric bedside manœuvres) | ||
Provoked by CSM | Worsened conduction with atropine/catecholamines | ||
Improved conduction with Atropine/catecholamines | Improved conduction with CSM | ||
Suggestive | Narrow QRS (however, intra-Hissian block may result in a narrow QRS!) | Wide QRS (however the patient may have nodal block with concomittent bundle branch block!) 2:1 or 3:1 AVB | |
BB, diltiazem, verapamil, digoxin | Flecainide, propafenone |
Drug | Effect | Dosage | Pharmacokinetics | Comments |
---|---|---|---|---|
Atropine | Muscarinic acetylcholine receptor antagonist | 0.5 mg i.v. (repeat every 3–5 minutes to max. 3 mg) | t½ 3−4hours. ~50% renal excretion. | Indicated in case of nodal block. Doses <0.5 mg may paradoxically worsen bradycardia. CI: glaucoma, prostatism, illeus |
Isoprenaline/ isoproterenol | Alpha-1, alpha-2, beta-1 and beta-2 adrenoreceptor agonist | Start infusion at 4 μg/min then up-/down-titrate over minutes to 1−10 μg/min based upon response | t½ 1 min | May not be well tolerated over many hours because of side effects (trembling, headache, etc) |
Adrenaline/ epinephrine | Alpha and beta adrenoreceptor agonist | Infusion 2–10 μg/min (titrate with response) | t½ 3 min followed by slower elimination (t½ 10 min) | Useful if hypotension is an issue (owing to vasoconstricting effect) |
Dopamine | Dopamine and alpha and beta adrenoreceptor agonist | Infusion 4−10 μg/kg/min | t½ 2 min | No bolus injections |
Dobutamine | Beta-1 adrenoreceptor agonist | Infusion 3−10 μg/kg/min | t½ 2 min | Useful if concurrent inotropic insufficiency |
Theophylline | Adenosine receptor antagonist and phosphodiesterase inhibitor | 100−200 mg slow i.v. injection | t½ 4−24 h (affected by age, smoking, hepatic function, drug interactions, etc.) | Infrequently used for treating bradycardia |
Aminophylline | Adenosine receptor antagonist and phosphodiesterase inhibitor | 200−300 mg slow i.v. injection | Infrequently used for treating bradycardia |
Drug causing bradycardia | Treatment | Comments |
---|---|---|
Beta-blocker | Glucagon | First-line antidote 2–10 mg bolus followed by 2–5 mg/h infusion |
Inotropes: adrenaline, dobutamine, isoprenaline | Competitive beta-receptor agonists High doses often required to overcome the effect of beta- blockade | |
Calcium channel blocker | Intravenous calcium | First-line antidote Partially overcomes calcium blockade Calcium chloride or calcium gluconate can be given as boluses or infusion—monitor levels |
Glucagon | Can be used as bolus or infusion: 2–10 mg bolus followed by 2–5 mg/h infusion | |
Digoxin | Digoxin-specific antibodies (Fab fragments) | First-line antidote Allergenic and expensive. Only to be used in life-threatening arrhythmias attributed to digoxin. |
© 2018 by the author. Attribution - Non-Commercial - NoDerivatives 4.0.
Share and Cite
Burri, H.; Dayal, N. Acute Management of Bradycardia in the Emergency Setting. Cardiovasc. Med. 2018, 21, 98. https://doi.org/10.4414/cvm.2018.00554
Burri H, Dayal N. Acute Management of Bradycardia in the Emergency Setting. Cardiovascular Medicine. 2018; 21(4):98. https://doi.org/10.4414/cvm.2018.00554
Chicago/Turabian StyleBurri, Haran, and Nicolas Dayal. 2018. "Acute Management of Bradycardia in the Emergency Setting" Cardiovascular Medicine 21, no. 4: 98. https://doi.org/10.4414/cvm.2018.00554
APA StyleBurri, H., & Dayal, N. (2018). Acute Management of Bradycardia in the Emergency Setting. Cardiovascular Medicine, 21(4), 98. https://doi.org/10.4414/cvm.2018.00554